Page 8 - Nasdaq Stro News Today : Breaking News, Live Updates & Top Stories | Vimarsana

- iADCs are a next-generation modality for treating cancer and designed to boost anti-cancer activity, offering potential new options for patients who do...

Sutro Biopharma (NASDAQ:STRO – Get Rating) and Talaris Therapeutics (NASDAQ:TALS – Get Rating) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends and earnings. Earnings & Valuation This table compares Sutro Biopharma and […]

Shares of Sutro Biopharma, Inc. (NASDAQ:STRO – Get Rating) have been assigned an average recommendation of “Buy” from the eight research firms that are currently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating on the company. The average twelve-month […]

Sutro Biopharma (NASDAQ:STRO – Get Rating) had its price objective cut by analysts at HC Wainwright from $35.00 to $30.00 in a note issued to investors on Wednesday, The Fly reports. HC Wainwright’s target price points to a potential upside of 462.85% from the company’s current price. Several other research firms have also recently weighed […]

Sutro Biopharma (NASDAQ:STRO – Get Rating) issued its quarterly earnings data on Monday. The company reported ($0.84) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.08), MarketWatch Earnings reports. Sutro Biopharma had a negative net margin of 170.55% and a negative return on equity of 32.96%. STRO traded up […]